Exogenous surfactant in the late respiratory phase of COVID-19

The patient with severe viral-bacterial pneumonia and veriﬁed COVID-19 was successfully treated with surfactant therapy in the late respiratory phase of the disease, surfactant therapy was used to reduce the degree of hypoxemia and accelerate the weaning from non-invasive mechanical ventilation (NIMV). The native surfactant was administered with inhalations at the dose of 75 mg 2times a day on the 5th day of NIMV since SpO2 values persisted to be 92-93% and did not improve. Positive changes were observed after 4 inhalations: SpO2 reached 95% and then remained within the range of 94-97% with FiO2 90%. In total, the patient received 10 inhalations, then she was gradually transferred to breathing through an oronasal mask with humidiﬁed oxygen.

show abstract

Inhalations with surfactant-BL in the late respiratory phase of COVID-19 in the patient with a severe course of the disease

Kudinova

Pasynkova²,

Аkimenko

2022

Tuberk. bolezni lëgk.

View full text Add to dashboard Cite

show abstract

Role of surfactant in the pathogenesis of bronchopulmonary pathology

Kharitonov,

Rudakov,

Salukhov

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Pulmonary surfactant is an important structure of the lungs, providing basic vital functions: reducing alveolar surface tension and facilitating breathing, preventing collapse of the airways and ensuring their patency, protection against infections and pathological environmental factors. Although disturbances of surfactant homeostasis are usually considered in the context of respiratory distress syndrome in preterm infants, it has been established that many lung diseases in adults are accompanied by significant disturbances of surfactant homeostasis. However, preclinical and clinical studies of bronchopulmonary pathology too often overlook the potential role of changes in the qualitative or quantitative composition of pulmonary surfactant in the pathogenesis and development of disease symptoms. In many lung diseases, whether these disturbances in homeostasis are cause or effect remains contravertial field. This review will examine current data on the composition, main functions of pulmonary surfactant and the role of its dysfunction in the pathogenesis of the most frequently encountered bronchopulmonary diseases in the practice of pulmonologists, therapists and rehabilitation specialists, in particular, such as acute respiratory distress syndrome in adults, including associated with a new coronavirus infection, pneumonia of various etiologies and their consequences, bronchial asthma, chronic obstructive pulmonary disease. The review presents the current best practices of replacement therapy with exogenous surfactant preparations and the prospects for pharmacological modulation of surfactant homeostasis disorders in the above nosological forms.

show abstract

Complex treatment of destructive pulmonary tuberculosis using inhaled tauractant therapy

Tatarintseva,

Batishcheva,

Demidkov

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Chemotherapy is the main component used in the treatment of tuberculosis. In addition to chemotherapy, pathogenetic treatment holds a special place in the complex treatment. The inhaled tauractant therapy restores phospholipid content on the surface of the alveolar epithelium, stimulates the involvement of additional lung parenchyma areas in breathing, facilitates elimination of toxic substances together with sputum from the alveolar space and protects the alveolar epithelium against injury caused by chemical and physical agents. Thereby it promotes acceleration of the lung parenchyma recovery processes.Aim. To study the experience of using Surfactant-BL in patients with destructive pulmonary tuberculosis receiving a standard chemotherapy regimen, taking into account the drug susceptibility for Mycobacterium tuberculosis.Materials and methods. A study was conducted involving 10 patients with destructive pulmonary tuberculosis who were diagnosed with it for the first time in their lives. They received treatment in Respiratory Tuberculosis Patients Department No. 4 of the Budgetary Healthcare Institution of Omsk Region – Clinical TB Dispensary in 2022–2023.Results. Tauractant showed a pronounced positive effect on the destructive tuberculosis process in patients who already received a standard chemotherapy regimen. Inhaled therapy promoted acceleration of the cavity closure.Conclusion. The addition of inhaled tauractant therapy to the standard chemotherapy regimen in patients with multidrug resistance (MDR) and pre-extensively drug-resistant (pre-XDR) respiratory TB significantly accelerated the TB cavity closure. The severity of intoxication and respiratory syndrome decreased in terms of clinical symptoms (relief of shortness of breath and cough). Spirography showed an increase in major indices of the pulmonary function test monitored at 2and 4-month follow-up.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Exogenous surfactant in the late respiratory phase of COVID-19

Cited by 4 publications

References 16 publications

Inhalations with surfactant-BL in the late respiratory phase of COVID-19 in the patient with a severe course of the disease

Inhalations with surfactant-BL in the late respiratory phase of COVID-19 in the patient with a severe course of the disease

Role of surfactant in the pathogenesis of bronchopulmonary pathology

Complex treatment of destructive pulmonary tuberculosis using inhaled tauractant therapy

Contact Info

Product

Resources

About